Vertiv (VRT)
(Delayed Data from NYSE)
$94.54 USD
+2.48 (2.69%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $94.47 -0.07 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRT 94.54 +2.48(2.69%)
Will VRT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRT
Why Vertiv is a "Strong Buy" Tech Stock and Long-Term AI Investment
5 Hidden Gem AI Stocks to Buy Now
VRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Growth Stocks to Buy for September 19th
AI & Space Stocks: Two Megatrends to Ride Over the Next Decade
Why Vertiv Holdings Co. (VRT) Outpaced the Stock Market Today
Other News for VRT
Janus Henderson Contrarian Fund Q2 2024 Commentary
5 Hidden Gem AI Stocks To Buy Now
Vertiv Holdings Co (VRT) Trading 3.34% Higher on Sep 19
A Closer Look at Vertiv Hldgs's Options Market Dynamics
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse